IFNG and neoplasm: The longitudinal biopsy sample analysis during neoadjuvant treatment in the DOMINI clinical trial has also shown that the tumor transition from IFN-γ-low to IFN-γ-high, at the third week of treatment, allows for the achievement of a pathological response in 50% of the patients treated with domatinostat plus nivolumab and 80% of the patients treated with domatinostat with nivolumab plus ipilimumab [40].